Fig. 3.

ZNF711 modulates CDDP resistance in EOC in vivo. (a) A intra-peritoneal tumor model was established in nude mice by inoculating the indicated stable HEY cell lines, and representative images of tumor-bearing nude mice were presented at the initial time of CDDP treatment (upper) and six weeks after CDDP treatment (lower) (left panel, n = 6/group). Relative changes in the bioluminescence signal of intra-peritoneal tumors in nude mice upon CDDP chemotherapy at the indicated time points (right panel). (b) Kaplan-Meier survival of tumor-bearing mice after CDDP treatment. (c) IHC staining of ZNF711 and PCNA and TUNNEL staining (left) and quantification (right) of ZNF711 expression, apoptotic rate, and proliferation index in the indicated xenograft tumors. Scale bars, 50 μm. (d) Content of intercellular CDDP in the indicated xenograft tumors. (e) The quantification of DNA-bound CDDP (Pt) in the indicated xenograft tumors. (f) Representative images of tumor-bearing nude mice formed by HEY/vector and HEY/ZNF711 cells (left) and relative changes in the bioluminescence signal upon CDDP chemotherapy at the indicated time points (right). (g) Overall survival of tumor-bearing mice after CDDP treatment. (h) IHC staining of ZNF711 and PCNA and TUNNEL staining (left) and quantification (right) of ZNF711 expression, apoptotic rate, and proliferation index in the indicated xenograft tumors. Scale bars, 50 μm. (i-j) The content of internal CDDP (i) and DNA-binding CDDP (j) in indicated tumors. Each bar shown in the figure represents the mean ± SD of three independent experiments. n = 6, *p < 0.05 (Fig. 3a-e using one-way ANOVA with Bonferroni's correction; Fig. 3f-j using Unpaired t test).